
A Looming FDA Decision, Approval Odds, Investor Takeaways
Late-stage biopharma Scholar Rock (SRRK) is approaching a pivotal catalyst: the FDA decision on apitegromab, its investigational muscle-targeted therapy for spinal muscular atrophy (SMA). A verdict is expected on September 22, and the company appears well- …